J. Castille

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19

V. Calvez, Y. Ngo, M. Rudler, 2020, PloS one.

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19

V. Calvez, Y. Ngo, M. Rudler, 2020, medRxiv.

Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus

K. Cusi, M. Mcphaul, J. Lai, 2018, Journal of Investigative Medicine.

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age

Y. Ngo, T. Poynard, V. Ratziu, 2011, BMC gastroenterology.

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity

Y. Ngo, T. Poynard, V. Ratziu, 2015, BMJ Open.

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference

Chris Day, Fritz Wrba, Debbie Lawlor, 2016, Alimentary pharmacology & therapeutics.

Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

Y. Ngo, T. Poynard, V. Ratziu, 2012, Journal of hepatology.

Prospective external validation of a new non‐invasive test for the diagnosis of non‐alcoholic steatohepatitis in patients with type 2 diabetes

V. Paradis, S. Czernichow, D. Valla, 2021, Alimentary pharmacology & therapeutics.